Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Harvard Business School
Baxter
Moodys
Johnson and Johnson

Last Updated: February 1, 2023

Details for Patent: 9,604,901


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 9,604,901
Title:Process to prepare treprostinil, the active ingredient in Remodulin.RTM.
Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
Inventor(s): Batra; Hitesh (Herndon, VA), Tuladhar; Sudersan M. (Silver Spring, MD), Penmasta; Raju (Herndon, VA), Walsh; David A. (Palmyra, VA)
Assignee: United Therapeutics Corporation (Silver Spring, MD)
Application Number:14/754,932
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,604,901
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound;

Drugs Protected by US Patent 9,604,901

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-001 May 21, 2002 AP RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-002 May 21, 2002 AP RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-003 May 21, 2002 AP RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-004 May 21, 2002 AP RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-005 Jul 30, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
United Therap TYVASO DPI treprostinil POWDER;INHALATION 214324-001 May 23, 2022 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
United Therap TYVASO DPI treprostinil POWDER;INHALATION 214324-002 May 23, 2022 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,604,901

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2710205 See Plans and Pricing
China 101903324 See Plans and Pricing
China 103274926 See Plans and Pricing
European Patent Office 2252570 See Plans and Pricing
European Patent Office 3287434 See Plans and Pricing
Spain 2630407 See Plans and Pricing
Japan 2011506599 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Harvard Business School
Dow
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.